Literature DB >> 16817736

Cartilage-derived biomarkers and lipid mediators of inflammation in horses with osteochondritis dissecans of the distal intermediate ridge of the tibia.

Janny C de Grauw1, Pieter A Brama, Peter Wiemer, Harold Brommer, Chris H van de Lest, P Rene van Weeren.   

Abstract

OBJECTIVE: To assess whether reported alterations in metabolism of cartilage matrix in young (0 to 24 months old) horses with osteochondritis dissecans (OCD) may also be found in older (24 to 48 months old) horses with clinical signs of OCD and to investigate the role of eicosanoids in initiating these clinical signs. SAMPLE POPULATION: Synovial fluid was collected from 38 tarsocrural joints of 24 warmblood horses with (22 joints of 16 horses) or without (16 joints of 8 horses) clinical signs and a radiographic diagnosis of OCD of the distal intermediate ridge of the tibia. PROCEDURES: Turnover of type II collagen was investigated by use of specific immunoassays for synthesis (carboxypropeptide of type II collagen [CPII]) and degradation (collagenase-cleaved fragments of type II collagen [C2C]) products. Furthermore, glycosaminoglycan (GAG), leukotriene (LT) B(4), cysteinyl LTs, and prostaglandin (PG) E(2) concentrations were determined, and concentrations in joints with OCD were compared with those in joints without OCD.
RESULTS: Concentrations of CPII, C2C, and GAG did not differ significantly between affected and nonaffected joints. Fluid from joints with OCD had significantly higher LTB(4) and PGE(2) concentrations than did fluids from nonaffected joints. CONCLUSIONS AND CLINICAL RELEVANCE: Altered collagen or proteoglycan turnover was not detected in 24- to 48-month-old horses at the time they developed clinical signs of OCD of the distal intermediate ridge of the tibia. However, increased concentrations of LTB(4) and PGE(2) in fluid of joints with OCD implicate these mediators in the initiation of clinical signs of OCD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16817736     DOI: 10.2460/ajvr.67.7.1156

Source DB:  PubMed          Journal:  Am J Vet Res        ISSN: 0002-9645            Impact factor:   1.156


  6 in total

1.  Coll2-1, Coll2-1NO2 and myeloperoxidase concentrations in the synovial fluid of equine tarsocrural joints affected with osteochondrosis.

Authors:  Denis R Verwilghen; Ann Martens; Evita Busschers; Thierry Franck; Michelle Deberg; Yves Henrotin; Laurent Vanderheyden; Didier Serteyn
Journal:  Vet Res Commun       Date:  2011-06-17       Impact factor: 2.459

2.  Treatment Effects of Intra-Articular Allogenic Mesenchymal Stem Cell Secretome in an Equine Model of Joint Inflammation.

Authors:  Clodagh M Kearney; Sohrab Khatab; Gerben M van Buul; Saskia G M Plomp; Nicoline M Korthagen; Margot C Labberté; Laurie R Goodrich; John D Kisiday; P R Van Weeren; Gerjo J V M van Osch; Pieter A J Brama
Journal:  Front Vet Sci       Date:  2022-06-22

3.  A genome-wide association study of osteochondritis dissecans in the Thoroughbred.

Authors:  Laura J Corbin; Sarah C Blott; June E Swinburne; Charlene Sibbons; Laura Y Fox-Clipsham; Maud Helwegen; Tim D H Parkin; J Richard Newton; Lawrence R Bramlage; C Wayne McIlwraith; Stephen C Bishop; John A Woolliams; Mark Vaudin
Journal:  Mamm Genome       Date:  2011-11-04       Impact factor: 2.957

Review 4.  Osteochondritis dissecans (OCD) in Horses - Molecular Background of its Pathogenesis and Perspectives for Progenitor Stem Cell Therapy.

Authors:  Lynda Bourebaba; Michael Röcken; Krzysztof Marycz
Journal:  Stem Cell Rev Rep       Date:  2019-06       Impact factor: 5.739

5.  Inflammatory mediators and cartilage biomarkers in synovial fluid after a single inflammatory insult: a longitudinal experimental study.

Authors:  Janny C de Grauw; Chris H A van de Lest; Paul René van Weeren
Journal:  Arthritis Res Ther       Date:  2009-03-09       Impact factor: 5.156

6.  The preventive effects of two nutraceuticals on experimentally induced acute synovitis.

Authors:  E van de Water; M Oosterlinck; M Dumoulin; N M Korthagen; P R van Weeren; J van den Broek; H Everts; F Pille; D A van Doorn
Journal:  Equine Vet J       Date:  2016-10-13       Impact factor: 2.888

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.